InsightsThe Bioverse journal
Tactical playbooks for founders who want to be seen.
No fluff. No "10 social media tips." Real strategies, proven systems, and uncomfortable truths about why most biotech marketing fails.
-
Agency guide · MethodologyThe Most Suitable Biotech Marketing Agencies for Different Needs in 2026
Ten agencies, scored against ten public-evidence criteria, including ourselves. Alphabetical, not ranked, because the right fit depends on your stage and budget.
- 02Fundraising · Investor psychology
The Founder Who Almost Missed Her Series A Because Google Got Her Wrong
She crushed both meetings. Her data was real. Her narrative was sharp. She still almost lost the round. What an investor found when he Googled her at 10:23pm tells you everything.
- 03Fundraising · Investor psychology
Why Investors Ignore Scientifically Brilliant Biotech Startups
Your science was never the reason for the pass. Here's what's actually happening inside an investor's head when brilliant biotech gets rejected.
- 04Fundraising · Strategy
How to Build Your Pre-Series A Narrative (Before You Open the Data Room)
The 90 days before a Series A are the highest-leverage content window in a biotech founder's career. Here's the system to use them intentionally.
- 05Playbook · LinkedIn
The Biotech Founder's LinkedIn Playbook for 2026
A step-by-step system for biotech founders who want to attract investors, partners, and talent through LinkedIn, without becoming a full-time content creator.
- 06Strategy · Content
Why Every Biotech Needs a Content Engine (Not a Blog)
A blog is a graveyard. A content engine is a compounding asset. Here's the structural difference, and how to build one that survives founder transitions.
- 07Fundraising
How Startups Attract Investors Using Content (Real Tactics)
Investors fund founders they recognize. Here's how to engineer that recognition before you even open the data room.
- 08Authority
How to Build Thought Leadership on LinkedIn (Without Posting Daily)
The myth of daily posting is killing biotech founders. Here's the high-leverage alternative, built around scientific credibility, not posting frequency.
- 09Growth
Why Social Media Is Replacing Cold Outreach in Biotech
Cold emails to biotech buyers convert at 0.4%. Inbound from LinkedIn authority converts at 8%. Here's why the math is shifting permanently, and what to do about it.
- 10AI · GEO/AEO
The Biotech AI Search Visibility Crisis (And How to Fix It)
Investors and BD execs are no longer Googling. They're asking ChatGPT. Here's what they're being told about you, and how to control the answer.
Newsletter
One playbook a month. Built for biotech founders.
Our deepest tactical breakdowns, delivered before they go public. No spam. Unsubscribe anytime.